The significance of genetic testing for melanoma patients mainly involves two aspects: first, the identification of specific driver gene mutations to guide the application of targeted drugs; second, the detection of mutations in some common genes to judge the prognosis of the disease. Regarding the target gene mutations for drug selection, the commonly used ones include mutations in C-KIT, BRAF, and M-TOR. If mutations in these target genes are found, corresponding targeted drugs can be used for treatment. These drugs are generally orally administered, have relatively good efficacy, low side effects, and are suitable for the treatment of melanoma. Additionally, some genetic tests can predict the prognosis of melanoma patients based on the presence or absence of mutations.